GLP-1 Receptor Agonists-From Breakthroughs in Cardiometabolic Treatment to Emerging Neuroprotective Potential

Affiliations

Diana Thiara. JAMA Neurol. 2025.

. 2025 May 1;82(5):437-438.

doi: 10.1001/jamaneurol.2025.0237.

¹ Division of General Internal Medicine, University of California, San Francisco.

No abstract available

Comment in

GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias.
Tang H, Donahoo WT, DeKosky ST, Lee YA, Kotecha P, Svensson M, Bian J, Guo J. Tang H, et al. JAMA Neurol. 2025 May 1;82(5):439-449. doi: 10.1001/jamaneurol.2025.0353. JAMA Neurol. 2025. PMID: 40193118
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.
Seminer A, Mulihano A, O'Brien C, Krewer F, Costello M, Judge C, O'Donnell M, Reddin C. Seminer A, et al. JAMA Neurol. 2025 May 1;82(5):450-460. doi: 10.1001/jamaneurol.2025.0360. JAMA Neurol. 2025. PMID: 40193122 Free PMC article.
GLP-1 Medications May Lower Dementia Risk, Research Shows.
Anderer S. Anderer S. JAMA. 2025 Jun 3;333(21):1855. doi: 10.1001/jama.2025.5640. JAMA. 2025. PMID: 40314947 No abstract available.